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Abstract
Ultimately, asthma is a disease characterized by constriction of airway smooth muscle (ASM). The
earliest approach to the treatment of asthma comprised the use of xanthines and anti-cholinergics
with the later introduction of anti-histamines and anti-leukotrienes. Agents directed at ion channels
on the smooth muscle membrane (Ca2+ channel blockers, K+ channel openers) have been tried and
found to be ineffective. Functional antagonists, which modulate intracellular signalling pathways
within the smooth muscle (β-agonists and phosphodiesterase inhibitors), have been used for
decades with success, but are not universally effective and patients continue to suffer with
exacerbations of asthma using these drugs. During the past several decades, research energies have
been directed into developing therapies to treat airway inflammation, but there have been no
substantial advances in asthma therapies targeting the ASM. In this manuscript, excitation-
contraction coupling in ASM is addressed, highlighting the current treatment of asthma while
proposing several new directions that may prove helpful in the management of this disease.
Background
Asthma is experienced during the life span of approxi-
mately 10% of the population, resulting in morbidity and
mortality costing a substantial economic burden on soci-
ety [1]. The predominant feature of asthma is the discom-
fort experienced upon breathing in the presence of
excessive and inappropriate constriction of the airway
smooth muscle (ASM). Although airway inflammation
may play an important role in asthma, it is benign in the
absence of airway narrowing. The patient is thus predom-
inantly concerned with narrowing of their airways, con-
tributing to an unpleasant increase in the effort required
to breathe; in the extreme, this increased effort fails to
allow sufficient ventilation, leading to morbidity and
even mortality. As such, ASM is ultimately a major target
in any management of asthma.
The earliest recorded treatments of asthma included
tobacco, indian hemp, sedation (using low doses of chlo-
roform, ether, or opium), ipecacuana, coffee, tea, stramo-
nium lobelia and other less effective agents. These agents
express the pharmacological properties of the xanthines,
cholinergic blockade, sympathetic stimulation, sedation
and direct smooth muscle relaxation. Direct approaches
using anti-cholinergics, anti-histamines, anti-leukot-
rienes, and functional antagonists modulating intracellu-
lar signalling pathways (β-agonists and
phosphodiesterase inhibitors) followed (section 3.2).
These have been used for decades with reasonable success,
but patients continue to suffer exacerbations of asthma.
Research energies were poured into developing new ther-
apies to treat airway inflammation to prevent rather than
treat the active disease. Asthma therapies using immune
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be so successful that targeting the ASM receded. Better
understanding of the mechanisms underlying contraction
of ASM is still essential to the management of the active
disease. In this manuscript, basic excitation-contraction
coupling in ASM is summarized and several new direc-
tions to the treatment of abnormal smooth muscle con-
striction are introduced.
Overview of excitation-contraction coupling
Asthma is characterized by excess reversible constriction
and airway hyperresponsiveness (AHR) to a wide variety
of spasmogens. Thus, it is essential to understand the
mechanisms underlying excitation-contraction coupling
of ASM. Contraction is triggered by phosphorylation of
myosin. This is catalyzed by Ca2+/calmodulin-dependent
myosin light chain kinase (MLCK), which in turn is acti-
vated as [Ca2+]i is elevated (see Fig. 1). Mechanisms intrin-
sic to the thin filament and Ca2+-sensitivity are also
involved and have the potential for therapeutic interven-
tion in modulating these basic responses.
Voltage-dependent mechanisms
Excitation-contraction coupling in cardiac, skeletal, vascu-
lar and gastrointestinal smooth muscles depends on
membrane depolarization resulting in Ca2+-entry via volt-
age-dependent ('L-type') Ca2+-channels. As such, Ca2+-
channel blockers and K+-channel openers are invaluable
in controlling cardiac and smooth muscle contractions in
hypertension, stroke, myocardial infarction, gastrointesti-
nal motility disorders, etc. [2-4]. Excitation of ASM is also
accompanied by membrane depolarization mediated pri-
marily by Ca2+-dependent Cl--- and non-selective cation-
channels, as well as activation of large voltage-dependent
Ca2+-currents. The latter can be sufficient to produce con-
traction, as indicated by the robust responses evoked by
potassium chloride or K+-channel blockers. As such, a nat-
ural conclusion would be that Ca2+-channel blockers
should be useful in the treatment of asthma: however,
they are essentially useless in this respect (see section 9.2).
Release of internal Ca2+
Internally sequestered Ca2+ plays an important role in
agonist-evoked responses in ASM. The sarcoplasmic retic-
ulum (SR) is central to this, acting as a sink to buffer
cytosolic [Ca2+]i, as well as providing an agonist-releasa-
ble store of Ca2+ to trigger contractions. Most, if not all,
bronchoconstrictor autacoids act through G-protein-cou-
pled receptors to stimulate phospholipase C activity and
subsequent generation of IP3, which in turn signals the SR
to release stored Ca2+ (Fig. 1). The mechanisms underly-
ing IP3- and ryanodine receptor-mediated release of inter-
nal Ca2+ and re-uptake of Ca2+ by the Sarcoplasmic/
Endoplasmic Reticulum Ca2+-ATPase (SERCA) are well
understood, although their relative roles in excitation-
contraction coupling may not be. Other aspects of Ca2+-
handling are very poorly understood, including the mech-
anism(s) by which the SR is refilled. Greater magnitude of
release of Ca2+ in cells/tissues pretreated with allergen or
pro-inflammatory cytokines has been documented [5-7].
However, there is little correlation between the magnitude
of the initial Ca2+-spike, which lasts only a few seconds,
and the subsequent contractile response which lasts many
minutes or hours. Other groups [8-13] are now focussing
their attention on the frequency of repetitive Ca2+-spikes
following agonist stimulation.
Changes in Ca2+-sensitivity
ASM cells also possess a myosin light chain phosphatase
(MLCP) which dephosphorylates myosin, limiting or
reversing airway contraction (see Fig. 1). If MLCP activity
is down-regulated, net myosin phosphorylation in
response to a given change in [Ca2+]i will be enhanced
and/or prolonged, resulting in greater contraction: in
other words, the Ca2+-sensitivity of the contractile appara-
tus is increased. At least two different signalling pathways
have been found to mediate increased Ca2+-sensitivity in
Bronchoconstrictors act on G-protein coupled receptors coupled t  a variety of signalling pathwaysFigure 1
Bronchoconstrictors act on G-protein coupled recep-
tors coupled to a variety of signalling pathways involv-
ing membrane depolarization (blue), release of internal Ca2+ 
(green), changes in Ca2+-sensitivity (red), and/or thin fila-
ment-mediated mechanisms (magenta).Page 2 of 12
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messenger liberated by phospholipase C) and protein
kinase C: the latter can phosphorylate CPI-17, which reg-
ulates MLCP activity.
The second pathway involves the monomeric G-protein
RhoA and its downstream effector molecule Rho-kinase
(ROCK). A decade of study in vascular smooth muscle has
revealed certain aspects of this signalling cascade (Fig. 2).
Inactive RhoA exists in the cytosol with its prenylated
hydrophobic tail inserted into its partner molecule, GDP
dissociation inhibitor (RhoGDI). G-protein-coupled
receptors, upon binding their respective ligands, activate
the heterotrimeric G-protein G12,13, which in turn triggers
one or more tyrosine kinases (c-Src, FAK, Fyn, etc.) and
other signalling molecules, culminating in the activation
of a Rho-specific guanine nucleotide exchange factor
(RhoGEF). Numerous GEFs have been identified in the
human genome, but the ones most studied include LARG,
PDZ-RhoGEF and p115 RhoGEF. These displace RhoGDI
and stimulate exchange of GDP for GTP, activating RhoA,
which translocates to the membrane and interacts with
ROCK. The latter in turn phosphorylates MLCP at two dif-
ferent threonine residues [14] – Thr696 (inhibiting its
phosphatase activity) and Thr853 (interfering with its tar-
geting of myosin) – ultimately leading to suppression of
MLCP activity. RhoA inactivates by hydrolyzing the GTP
bound to it (catalyzed by Rho-GTPase activating protein,
or RhoGAP) and re-associating with RhoGDI.
Much of the data summarized above were derived from
vascular smooth muscle, which may not be applicable to
ASM. There are many examples of how these two tissue
types can operate quite differently. For example, the two
differ dramatically with respect to the role of Ca2+/cal-
modulin-dependent protein kinase II in activation of
RhoA [15]. Likewise, both airway and vascular smooth
muscle have exactly the same cellular machinery for volt-
age-dependent contractions, but have diametrically oppo-
site dependence upon that pathway. Very little is known
about the regulation of the Rho/ROCK signalling pathway
in ASM, but its exploration may provide novel targets for
therapeutic intervention.
Thin filament-mediated mechanisms
All of the signalling mechanisms summarized above are
directed in one way or another at phosphorylation/
dephosphorylation of myosin (i.e., the "thick filament").
Emerging data now also point to a number of mecha-
nisms pertaining specifically to actin (the "thin filament")
[16]. In particular, calponin and caldesmon both interact
with F-actin and myosin and inhibit actomyosin ATPase
activity. Both are regulated by adrenoceptor-stimulated
PKC- and ERK-activities: the latter mediate changes in the
phosphorylation state and/or localization of caldesmon
and calponin, leading to removal of inhibition of actin,
resulting in contraction.
Evolution of asthma therapy
By and large, the advances made in our understanding of
excitation-contraction coupling in ASM have been driven
largely from other fields, first in skeletal muscle and later
vascular smooth muscle, neither of which are good mod-
els for ASM physiology (since their physiology is quite dif-
ferent from that of ASM).
Basic pharmacology of excitation of ASM
Knowledge of the innervations of the airway and the
response of ASM to circulating hormones initiated current
therapies. The excitatory innervation of ASM is parasym-
pathetic, exerting its actions primarily through muscarinic
cholinergic receptors [17;18]. Cholinergic receptor block-
ers progressed from belladonna and stramonium
lobeline, leading eventually to atropine. Atropine had
substantial side effects, given its pleiotropic effects
throughout the body. The inhaled route was exploited to
direct treatment to the airway but absorption into the cir-
culation led to distal side effects. Ipratropium bromide,
not readily absorbed into the bloodstream, eliminated the
major side effects, and is an effective bronchodilator. Anti-
cholinergics, including ipratropium and its long-acting
equivalent tiotropium, have been used to treat asthma but
in general adrenergic agents are preferred. Anti-choliner-
gic agents are used with acute severe asthma but are not
broadly used in the day-to-day management of mild to
Summary of Rho/ROCK signalling cascadeFigure 2
Summary of Rho/ROCK signalling cascade.Page 3 of 12
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useful (e.g., M2- and M3-selective blockers).
Sympathetic stimulation relaxes ASM. The finding that the
effects of sympathetic stimulation were mimicked by
adrenalin (discovered at the turn of the last millenium)
and noradrenalin led to the discovery of chemical neuro-
transmission. In the 1940's the concept of adrenergic
receptor subtypes arose due to the different effects of
adrenalin on different tissues. This ultimately led to the
discovery of specific agonists causing ASM relaxation (β2-
receptor agonists). Short- and long-acting β-agonists are
now the most widely used bronchodilating agents.
The airways of some species including man exhibit a non-
adrenergic, non-cholinergic innervation which make a
minor contribution to ASM activity. The agonist for this
system is still debated, but may include nitric oxide. As
such, nitric oxide may provide a useful target for the treat-
ment of asthma.
Asthma precipitated by allergen exposure in sensitized
subjects provides a useful experimental model. Allergen
binds to IgE on the surface of mast cells following inhala-
tion leading to the immediate release of histamine, which
in turn causes an immediate ("early") bronchoconstrictor
response within 10 minutes and lasting approximately 90
minutes. Histamine acts on H1 receptors on the ASM,
which in turn are coupled to the same signalling pathways
utilized by muscarinic receptors (namely, activation of the
phosphoinositide cascade, release of internally seques-
tered Ca2+ and possibly Rho/ROCK-mediated enhance-
ment of Ca2+-sensitivity). Anti-histamines have been
proven to be partially effective in the treatment of asthma
[18].
The early response is followed 6–8 hours later by a second
more prolonged bronchoconstriction lasting many hours
or even days, mediated in part by a "slow-reacting sub-
stance of anaphylaxis", or SRSA [19]. Upon further inves-
tigation, leukotrienes proved to be the mysterious SRSA,
leading to the award of a Nobel Prize [94]. In addition to
their actions on various inflammatory cells (largely medi-
ated by LTB4), leukotrienes act on cys-LT1 receptors on the
ASM: the latter are also G-protein-coupled receptors and,
once again, act through stimulation of the phosphoi-
nositide signalling cascade and of the Rho/ROCK-medi-
ated change in Ca2+-sensitivity. This led to the
development of blockers of those receptors and of leuko-
triene synthesis (lipoxygenase inhibitors). The efficacy of
these agents in the treatment of asthma has been less than
that initially expected but these compounds are widely
used.
Functional antagonism of a "convergent signalling 
pathway" in ASM
Ironically, the disappointing results of the therapeutic
strategies summarized above appear to be due in part to
the exceptional pharmacological selectivity of the agents
being used. The airways receive numerous excitatory
inputs, each acting exclusively on its own distinct plasma-
lemmal receptor (Fig. 3), and asthma is accompanied by
non-specific AHR to a wide variety of excitatory stimuli. As
such, an approach which interrupts the intracellular sig-
nalling pathways used by many/all of the excitatory stim-
uli is an exciting prospect.
It was hoped that one such common pathway was voltage-
dependent Ca2+-influx. The latter is of central importance
in cardiac, skeletal, vascular and gastrointestinal muscles,
and Ca2+-channel blockers are highly useful in many dis-
eases of those tissues [20,21]. There are many lines of evi-
dence which suggest voltage-dependent Ca2+-influx
should also be important in ASM, including the depolar-
izing influence of bronchoconstrictors, the hyperpolariz-
ing influence of bronchodilators, the abundance of the
very same type of Ca2+-channel as is present in the non-
airway muscles listed above, and the substantial contrac-
tions evoked in ASM by high millimolar potassium chlo-
ride. It was natural, then, to believe that asthma might
also be treated using Ca2+-channel blockers: however, this
approach has proven to be useless [22-28]. Despite this
setback, others went on to test the potential efficacy of K+-
channel openers in the treatment of asthma, even though
the underlying rationale for such an approach is identical
to that of using Ca2+-channel blockers (i.e, to hyperpolar-
ize the membrane such that Ca2+-channels are deacti-
vated). Not surprisingly, this approach was also found to
be completely ineffective [29-32]. These and many other
findings accumulated over decades of research are most
simply interpreted as indicating that voltage-dependent
Ca2+-influx is not centrally important in ASM contraction
and asthma. Nonetheless, even today there still appears to
be a tacit adherence to the dogma that such electrome-
chanical coupling is important. A better understanding of
contraction/relaxation in ASM demands a new emphasis
on mechanisms which are independent of membrane
potential (see below).
Another major line of research focussed on those stimuli
which exert an inhibitory (i.e., relaxant) influence on the
ASM. The predominant inhibitory innervation is adrener-
gic in nature, with the neurotransmitter norepinephrine
and circulating catecholamines (particularly epinephrine)
acting on β-adrenoceptors (more specifically β2-subtype
in human and many other species). Binding of these lig-
ands to the β2-receptors leads to stimulation of adenylate
cyclase, production of cAMP and consequent increase in
protein kinase A activity, which in turn mediates manyPage 4 of 12
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choconstrictor agents: vis-a-vis, decreased cytosolic levels
of Ca2+ (through a variety of actions on plasmalemmal K+-
and Ca2+-channels [33], as well as the Ca2+-pumps on the
plasmalemma and the SR [34]), inhibition of the RhoA/
ROCK signalling pathway [35] and direct stimulation of
MLCP [34]. A more recent development which builds on
the knowledge of the actions of cAMP on ASM has been
the application of phosphodiesterase inhibitors in the
treatment of asthma. These suppress the hydrolysis of
cAMP, allowing greater and more prolonged actions upon
adrenergic stimulation.
Anti-inflammatory agents
Given that many of the manifestations of asthma are trig-
gered directly or indirectly by inflammation, asthma treat-
ment is closely allied with immunology. The strategy of
interfering with the inflammatory response using an ever
longer list of corticosteroids, inhibitors of leukotriene syn-
thesis or leukotriene receptors, blockers of IgE receptors,
or of cytokines has been undoubtedly successful. The past
decade or two has witnessed a massive research effort to
better understand the inflammatory response, with
immense resources and energies being directed at identi-
fying newer anti-inflammatory agents. A full description
of this body of research is beyond the scope of this com-
munication. Prevention of asthma through these strate-
gies is important but treatment of the acute
bronchoconstriction will always be required. "If airway
inflammation didn't cause acute bronchoconstriction,
asthma might be a more tolerable disease" [36]. The most
effective strategy to acutely dilate an airway will always be
predicated on understanding the process of excitation-
contraction coupling (above) and exploiting those mech-
anisms. An increasingly familiar experience is inadequate
treatment of the airflow limitation associated with
asthma.
Novel directions
Despite all the advances summarized above, and the phar-
macological interventions which have arisen from them,
it still remains that asthma is not well controlled in many
individuals. Clearly, different approaches need to be
developed. Acetylcholine, histamine and leukotrienes all
act through a convergent signalling pathway (Fig. 3): the
same is true for other spasmogens such as endothelin,
serotonin, substance P, etc.. Appreciation of this fact
allows for several potential novel targets to be explored.
The non-specific nature of airway hyperreactivity and a convergent signalling pathway for spasmogens: hope for a novel therapy for asthma?Figure 3
The non-specific nature of airway hyperreactivity and a convergent signalling pathway for spasmogens: hope 
for a novel therapy for asthma? ASM receives diverse excitatory inputs from the innervation, inflammatory cells, and the 
epithelium, all of which act through distinct receptors, but a common signalling pathway. In asthma, the smooth muscle exhibits 
increased sensitivity to a wide range of excitatory stimuli. The non-specific nature of airway hyperreactivity suggests that some 
post-receptor mechanism(s) within the smooth muscle per se is altered. Spasmogens act through a convergent signalling path-
way involving Ca2+-handling and RhoA.Page 5 of 12
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All of the bronchoconstrictor stimuli referred to above act
through G-protein-coupled receptors to stimulate Ca2+-
release. In contrast to the relative impotence of blockers of
voltage-dependent Ca2+-influx, a long and ever-growing
list of in vitro studies of isolated airway tissues attests to
the much greater effect of inhibiting IP3-induced Ca2+-
release or of depleting the SR using blockers of SERCA. A
major drawback is that this Ca2+-homeostatic pathway is
central in nearly every cell type in the body, and therefore
seems to fail to offer a sufficiently selective target. How-
ever, the same criticism can be levelled at many of the
other therapeutic approaches which have already been
tried (e.g., targeting cAMP). It may be possible to identify
components of the Ca2+-homeostatic pathway which are
specific to ASM, and/or to limit delivery of agents by hav-
ing patients inhale modulators of this pathway.
Recently, a great deal of attention has been focussed on
the mechanisms underlying refilling of the SR. In many
cells, depletion of the internal Ca2+-store triggers a Ca2+-
influx pathway. We have begun to characterize a mem-
brane current which is evoked in ASM by depletion of the
SR using the SERCA inhibitor cyclopiazonic acid [37].
This current exhibits many electrophysiological and phar-
macological properties in common with Ca2+ store deple-
tion-activated currents in other cell types referred to as
TRP (Transient Receptor Potential) currents [38,39]. Sur-
prisingly, several recent reviews [38,40,41] have high-
lighted the potential of TRP-channels as therapeutic
targets in ASM, despite the fact that there had not yet been
any direct electrophysiological data pertaining to TRP cur-
rents in ASM: up to that point, the supporting data for
these currents had been obtained exclusively from studies
using fluorimetric Ca2+-dyes (which poorly discriminate
Ca2+-influx pathways) or very indirect approaches based
on mechanical responses as indices of Ca2+-handling. In
both cases, the studies have relied on the dubious selectiv-
ities of a variety of pharmacological tools.
Several groups including our own have published data
which suggest voltage-dependent Ca2+-channels may also
contribute to refilling and maintenance of the SR [42-47].
More surprisingly, our data suggest that this refilling path-
way in ASM does not involve SERCA, but some novel
interaction of the SR and the plasmalemma which allows
Ca2+ to flow directly from the extracellular space into the
SR [42,43]. Elsewhere, a model has been proposed which
describes one such interaction [48-53]. Briefly, agonist-
induced depletion of the internal store triggers activation
of protein tyrosine kinases and Ras: these cause the
cytoskeleton to re-organize in such a way as to directly
couple IP3-receptors on the SR with Ca2+-channels on the
plasmalemma. Several observations made in ASM are
consistent with such a mechanism: (i) spasmogenic stim-
ulation of ASM is accompanied by activation of tyrosine
kinases [54-56] and Ras/Rho [57-60], as well as cytoskel-
etal rearrangement [55,59-61]; (ii) tyrosine kinase inhibi-
tion compromises SR refilling [62]; (iii) ASM depleted of
FAK (which regulates cytoskeleton stability) shows
marked suppression of cholinergic Ca2+-transients and
contractions as well as changes in voltage-dependent
Ca2+-channel function, without any disruptive changes in
the contractile apparatus per se (assessed by addition of
Ca2+ to permeabilized strips) [63]. However, the possible
role for this novel SR refilling pathway has not yet been
tested in ASM: its presence and operation in ASM would
supply another potential target for the treatment of
asthma.
Other groups are calling attention to the temporal dynam-
ics of Ca2+-signalling rather than merely the amplitude of
the Ca2+-responses. That is, they show that excitatory stim-
uli do not simply trigger a solitary rise and fall of [Ca2+]i,
but rather a series of repetitive Ca2+ "spikes" or "waves".
More importantly, their data indicate that the strength of
the contractile response evoked by a bronchoconstrictor
depends not so much on the absolute peak magnitude of
the Ca2+-elevation, but rather the frequency of the Ca2+
waves [64,65]. As such, it may soon prove possible to
modulate airway constriction using agents which modu-
late Ca2+-wave frequency. That is, rather than merely
blocking the channels which release internally seques-
tered Ca2+ from the SR, it may be possible to modulate the
kinetics of their activation, thereby affecting the onset of
each Ca2+-spike. Alternatively, the cellular effectors which
determine the decay or resolution of each Ca2+-spike may
offer useful targets: these include the Ca2+-release chan-
nels themselves (perhaps it might be possible to accelerate
their deactivation or inactivation), as well as the cellular
entities which restore [Ca2+]i to resting levels (the plasma-
lemmal Ca2+-pump, SERCA and Na+/Ca2+ exchange).
Cl---channels
ASM exhibits large Cl-- currents in response to excitatory
stimuli, and these are tightly regulated by second messen-
ger signalling events [66-72]. It is usually concluded that
Cl-- currents are important for excitation-contraction cou-
pling by depolarizing the membrane and thus triggering
voltage-dependent Ca2+-influx, and would for this reason
provide a potential target for asthma therapy. However,
this therapeutic approach should be no more effective
than suppressing voltage-dependent Ca2+-influx using
Ca2+-channel blockers or K+-channel openers (neither of
which have proven to be effective). Why, then, are Cl---
channels so prominent in ASM?
A Cl---channel has been isolated from ASM with proper-
ties similar to those on the SR of skeletal and cardiac mus-
cle where they facilitate Ca2+-flux by neutralizing chargePage 6 of 12
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proposed an entirely novel and testable hypothesis [74]:
that agonists activate Cl-- currents in ASM in order to facil-
itate Ca2+-release/uptake. That is, Ca2+-efflux from the SR
leads to a net negative charge on the inner face of the SR
membrane which hinders Ca2+-release unless alleviated
by compensatory fluxes of Cl-- out of the SR. Given that
the agonists trigger substantial plasmalemmal Cl-- cur-
rents, the sudden loss of Cl-- from the subplasmalemmal
space would instantaneously alter the equilibrium poten-
tial for Cl-- across the SR membrane, thereby facilitating
efflux of Cl-- (and Ca2+) from the SR. Consistent with this,
we found contractions evoked by various stimuli includ-
ing caffeine to be reduced by removing external Cl-- [75];
interestingly, reintroduction of Cl-- restored the initial
peak response, suggesting normal refilling of the SR.
Cytosolic [Cl--] may also modulate RhoA/ROCK signal-
ling in ASM. While characterizing the agonist-evoked Cl---
currents in canine ASM, we noted contractions could be
evoked repeatedly during voltage clamp at -60 mV (at
which voltage-dependent Ca2+-channels are not open)
and in the presence of cyclopiazonic acid [43]: such con-
tractions are clearly independent of both voltage-depend-
ent Ca2+-influx and release of internal Ca2+ and therefore
likely involve altered Ca2+-sensitivity of the contractile
apparatus. More importantly, we found that cells which
were perfused internally with a Cl---deficient electrode
solution quickly lost the ability to contract [70]. One
interpretation of these findings is that Cl-- is somehow
essential to Rho and/or ROCK activation. Consistent with
that, we have found that the Cl---channel blocker niflumic
acid markedly suppresses cholinergically-induced RhoA-
activation. Changes in subplasmalemmal [Cl--] might
facilitate translocation of RhoA to the membrane, or
enhance interactions between the different components
of this signalling cascade. Others have shown G-protein
activity to be modulated by [Cl--] [76]. Alternatively, it
might be possible that changes in cytosolic [Cl--] some-
how affect ROCK activation and/or kinetics.
RhoA/ROCK signalling
An ever growing literature attests to the importance of the
RhoA/ROCK signalling pathway in increased Ca2+-sensi-
tivity of smooth muscle in general. ROCK inhibitors are
effective as bronchodilators [35,77-79]. Increased RhoA/
ROCK activities have been documented in allergic models
of asthma [80-86]. However, little is known about the
details underlying activation and modulation of this sig-
nalling pathway in ASM. Work done in vascular smooth
muscle, or even non-muscle preparations, may not be
equally applicable in ASM, as exemplified in the great deal
of time and effort spent, and lost, on studying voltage-
dependent Ca2+-influx in ASM. Also, although many have
examined stimulation of the RhoA/ROCK signalling path-
way by excitatory agonists [77,79,87-90], very few have
looked at the effects of relaxant agonists on this pathway.
Recently, we were the first to measure directly the activities
of RhoA and ROCK in ASM using immunoprecipitation
pull-down and radiometric enzyme assays [15,35,88],
and so documented the kinetics of activation of these two
signalling molecules: RhoA becomes activated within sec-
onds, reaching a peak within 2 minutes, but then falls
back toward baseline even though tone continues to
build. We also described the inhibitory effects, particu-
larly on ROCK activity, of two different β-agonists – iso-
proterenol (a short-acting, non-selective β-agonist with
full agonist activity) and salmeterol (a long-acting, β2-
selective agonist with only partial agonist activity), both
of which signal through stimulation of adenylate cyclase
activity – and a nitric oxide donor (S-nitroso-N-acetylpen-
icillamine; acting through stimulation of guanylate
cyclase).
Many of the details underlying RhoA/ROCK activation
remain to be explored. We were the first to show in ASM
that RhoA is activated by potassium chloride [88]. Follow
up work showed that this is directly related to elevated
[Ca2+]i, although membrane depolarization per se may
also be involved. Changes in ROCK activity parallelled
those in RhoA, suggesting KCl is not exerting an addi-
tional effect on ROCK (i.e., is only stimulating RhoA).
How might Ca2+ and membrane voltage stimulate RhoA
activity? It may be that Rho-activation is Ca2+-dependent,
although this explanation must explain the relative ineffi-
cacy of Ca2+-channel blockers. Alternatively, proteins are
charged molecules, and those which need to translocate to
the membrane must by influenced by the transmembrane
voltage gradient. On the other hand, there is a growing lit-
erature describing direct physical interactions between
various enzymes and ion channels, including "L-type"
Ca2+-channels [91,92]. It is possible that depolarization-
induced conformational changes in the channel proteins
are transduced to accessory cytosolic proteins including
RhoA; Ca2+-channel blockers do not necessarily affect
those conformational changes, which could explain why
ASM is refractory to that class of drug. None of these pos-
sibilities have been explored sufficiently.
Finally, the downstream targets which ROCK must phos-
phorylate to evoke contraction have not been examined in
detail. MLCP may be the primary target [93]. However,
data from non-airway tissues suggest that ROCK also
phosphorylates myosin light chain per se [94,95], ezrin/
radixin/moesin family proteins [96-99], elongation fac-
tor-1α [100], adducin [99,101], intermediate filaments
[102-104], and LIM-kinase [105,106]. There likely are
other targets which have not yet been revealed.Page 7 of 12
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to normalize hypercholesterolemia [107]. However, it is
now becoming clear that their beneficial effects may not
only lie in their ability to decrease cholesterol synthesis
per se [108]. Geranylgeranylpyrophosphate, an isoprenoid
intermediate arising from this biosynthetic pathway, is
essential in the activation of RhoA. As such, statins may
also act by suppressing Rho/ROCK signalling, a pharma-
cological action which might be exploited in asthma.
Tyrosine kinase(s)
We have shown the non-specific tyrosine kinase inhibitor
genistein to have powerful inhibitory effects on choliner-
gic responses in ASM [89]. However, the identity of the
tyrosine kinase(s) and the target(s) of its stimulation are
largely unclear. There is currently a great deal of attention
being focussed upon the role(s) of FAK in cholinergic
responses in ASM [109-111]: upon stimulation, FAK can
be autophosphorylated on tyrosine 397, recruiting other
non-receptor PTKs such as pp60src and pp59fyn (via their
SH2 domains), which can create additional tyrosine phos-
phorylation on other residues of FAK. Also, there is reason
to believe that tyrosine phosphorylation is part of the
RhoA signalling pathway (leading to activation of Rho-
GEF) as well as to Ca2+-handling in ASM [54]. Thus, tyro-
sine kinase inhibitors could prove valuable in the
treatment of asthma, if a sufficiently selective molecule
can be found.
Actomyosin ATPase activity and cross-bridge cycling
Rather than interfering with various "up-stream" signal-
ling events, it could be much more effective to target the
penultimate step in excitation-contraction coupling. Acti-
vation of actomyosin ATPase activity, through the phos-
phorylation of myosin light chain, and cross-bridge
cycling are the final determinants in the overall cascade of
events leading to contraction. A direct inhibitor of MLCK
could be far more effective than intervening further
upstream using β-agonists and phosphodiesterase inhibi-
tors. On the other hand, MLCP offers a tantalizing target:
the identification of a compound which directly, and
hopefully selectively, stimulates this activity would be
equally effective in the treatment of asthma. In contrast to
the extensive literature at hand pertaining to kinases and
the availability of innumerable "selective" kinase inhibi-
tors, the phosphatase field is still in its infancy: relatively
few selective inhibitors are yet available, perhaps in part
because the actual catalytic subunit of these enzymes acts
non-selectively on a wide variety of substrates but is
brought into proximity of a specific substrate by the tar-
geting subunit. As such, perhaps the targeting subunit
should itself be targeted by researchers. Clearly, any puta-
tive MLCK inhibitors or MLCP stimulants to be developed
for use in asthma would have to contend with the issue of
unwanted systemic effects, given the importance of these
enzymes in a wide variety of processes and cell types.
However, as pointed out above, it may be possible to limit
the systemic delivery of any trial compounds by develop-
ing them as inhaled agents and/or using gene therapeutic
approaches.
The so-called thick filament-mediated mechanisms –
those centering around myosin – have eclipsed research in
ASM excitation-contraction coupling in large part, and the
development of anti-asthma therapies in total. The grow-
ing understanding of the importance of thin filament-
mediated mechanisms in smooth muscle contraction may
eventually reveal other therapeutic approaches for dealing
with airway bronchospasm.
Approaches designed to decrease ASM mass per se
A radically different approach would be to ablate the ASM
itself, rather than modulate its activity. The question of
"why do we have airway smooth muscle" has been raised
repeatedly in the past with no convincing and satisfying
answers yet (this question is deftly reviewed in ref. [112]).
An exciting new development in this arena has been the
controlled delivery of thermal energy to the airways using
an intrabronchial catheter: a process now referred to as
bronchial thermoplasty [113,114]. This technique was
originally intended to serve as a treatment for chronic
obstructive pulmonary disorder, in which collapse of the
airways and gas trapping is a major problem: as such, the
thought was that inducing scarring of the airways might
make them stiffer and thus remain patent. Instead, no
scarring is evident and the airways look completely nor-
mal except for the peculiar absence of smooth muscle
cells; patients also commented on improved lung func-
tion and reduction of symptoms related to asthma. Pre-
clinical development-stage work was done in dogs, and
included a long series of studies aimed at determining the
intensity and duration of delivery of radiofrequency
energy required to achieve 50% reduction in ASM mass.
The procedure was next tested in a small group of mild
asthmatics, and is now being tested in a group of moder-
ate-severe asthmatics. The success of this approach under-
scores the potential value in developing other means to
eradicate the ASM, including the smaller airways. It may
be possible to develop toxic chemical interventions which
could be delivered specifically to the ASM (e.g., via gene
therapeutic approaches). Further studies of the cell cycle
of ASM are essential, since it may eventually be possible to
inhibit ASM proliferation and/or promote ASM apopto-
sis, both of which would achieve the same desired goal of
decreasing overall ASM muscle mass. Likewise, a better
understanding of ASM migration could lead to the devel-
opment of agents which prevent the hypertrophy/hyper-
plasia which accompany asthma.Page 8 of 12
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As stated above, there have not been any substantially new
pharmacological advances in the past decade or two with
respect to treatment strategies for asthma which target the
ASM. Admittedly, there have been newer β-agonists or
phosphodiesterase inhibitors, but these represent only
modifications of decades-old strategies. Any truly new
advances have been aimed at controlling inflammation,
which is also important but should not eclipse any efforts
aimed at controlling bronchoconstriction directly. We
have stated repeatedly that a better understanding of the
mechanisms underlying ASM contraction and AHR is a
prerequisite for any such new advances, and that it would
be unwise to base any such understanding solely on work
being done in the vascular smooth muscle field, let alone
others studying non-muscle tissues.
Physiological studies have for too long suffered from
important design flaws and limitations. First, the vast
majority of studies have been done using tracheal smooth
muscle rather than the smaller airways which are far more
important in determining resistance to airflow and which
are the clinically relevant site of airway inflammation:
compounding this shortsightedness is the growing body
of literature which shows major structural and functional
differences between the large and small airways. Also, too
many use maximally effective concentrations of excitatory
stimuli – e.g., near millimolar concentrations of choliner-
gic agonists – even though such degrees of stimulation are
rarely (if ever) reached in nature; this problem is exacer-
bated by numerous studies which suggest the relative con-
tributions of various signalling events can vary over the
full range of a concentration-response relationship.
Mitchell and Sparrow have elegantly shown that only the
lower half of the full concentration-response relationship
may be relevant, since complete airway closure can occur
at roughly the half-maximally effective concentration
[115]. As such, any further increase in tension seen at
higher concentrations would be completely occult: thus,
we need to focus instead on submaximal or even thresh-
old responses. Related to this point, many are now show-
ing that isotonic recordings (in which the muscle shortens
as tone develops) capture information which is unavaila-
ble or distorted in isometric studies (the mainstay of most
studies of ASM physiology and pharmacology). Finally,
the bulk of the data pertaining to this matter were
obtained under static conditions, whereas very recent
work now shows ASM function to be powerfully modu-
lated by mechanical perturbations (stretch; deep inspira-
tions; etc.) [116-118]. It is becoming increasingly clear
that this is related to a dynamic re-organization of the
actin and myosin filaments during contraction. This adap-
tation of ASM to its microenvironment ('plasticity') may
explain many lung/airway phenomena and offer clues for
novel therapeutic intervention.
A major and fundamental limitation in studies aimed at
better understanding and treating asthma has been the
lack of a good animal model of asthma. Asthma is charac-
terized, in part, by AHR, reversible bronchoconstriction,
wheezing, inflammation, and cellular changes related to
the muscle (hypertrophy and/or hyperplasia), epithelium
(denudation; mucous production), and inflammatory
cells (infiltration; degranulation; phenotypic changes).
There are many animal models which feature a degree of
AHR (e.g., induced by allergens or noxious agents) which
may or may not be accompanied by inflammation, or
which reproduce many features of airway inflammation
without a change in ASM responsiveness. Regarding those
studies which do find AHR in an experimental model, this
is usually minor compared to that seen in asthmatics:
there is generally only a modest increase in the maximal
response and a slight leftward shift, compared to the dra-
matic shift of several log units in the human condition.
Animals do not wheeze (although horses can manifest
heaves). In summary, there is no animal model which
reproduces fully all the features of asthma. Ultimately, our
goal should be to better understand excitation-contrac-
tion coupling in human ASM, and changes in that cou-
pling should be studied in tissues from asthmatics.
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